JP5507791B2 - ピリミジンを含有するｎｎｒｔｉとｒｔインヒビターとの組み合わせ物 - Google Patents

ピリミジンを含有するｎｎｒｔｉとｒｔインヒビターとの組み合わせ物 Download PDF

Info

Publication number
JP5507791B2
JP5507791B2 JP2006525150A JP2006525150A JP5507791B2 JP 5507791 B2 JP5507791 B2 JP 5507791B2 JP 2006525150 A JP2006525150 A JP 2006525150A JP 2006525150 A JP2006525150 A JP 2006525150A JP 5507791 B2 JP5507791 B2 JP 5507791B2
Authority
JP
Japan
Prior art keywords
tmc278
reverse transcriptase
hiv
combination
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2006525150A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007520443A (ja
Inventor
ストフエルズ，パウル
Original Assignee
ヤンセン・アールアンドデイ・アイルランド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5507791(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ヤンセン・アールアンドデイ・アイルランド filed Critical ヤンセン・アールアンドデイ・アイルランド
Publication of JP2007520443A publication Critical patent/JP2007520443A/ja
Application granted granted Critical
Publication of JP5507791B2 publication Critical patent/JP5507791B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2006525150A 2003-09-03 2004-09-03 ピリミジンを含有するｎｎｒｔｉとｒｔインヒビターとの組み合わせ物 Expired - Lifetime JP5507791B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US49977103P 2003-09-03 2003-09-03
EP03103275 2003-09-03
EP03103275.8 2003-09-03
US60/499,771 2003-09-03
EP03103319 2003-09-08
EP03103319.4 2003-09-08
EP03103335 2003-09-10
EP03103335.0 2003-09-10
EP03103668 2003-10-02
EP03103668.4 2003-10-02
US50848603P 2003-10-03 2003-10-03
US60/508,486 2003-10-03
PCT/EP2004/052028 WO2005021001A1 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011224982A Division JP2012051915A (ja) 2003-09-03 2011-10-12 ピリミジンを含有するｎｎｒｔｉとｒｔインヒビターとの組み合わせ物

Publications (2)

Publication Number Publication Date
JP2007520443A JP2007520443A (ja) 2007-07-26
JP5507791B2 true JP5507791B2 (ja) 2014-05-28

Family

ID=34280181

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006525150A Expired - Lifetime JP5507791B2 (ja) 2003-09-03 2004-09-03 ピリミジンを含有するｎｎｒｔｉとｒｔインヒビターとの組み合わせ物
JP2011224982A Withdrawn JP2012051915A (ja) 2003-09-03 2011-10-12 ピリミジンを含有するｎｎｒｔｉとｒｔインヒビターとの組み合わせ物
JP2014222770A Expired - Lifetime JP5820045B2 (ja) 2003-09-03 2014-10-31 ピリミジンを含有するｎｎｒｔｉとｒｔインヒビターとの組み合わせ物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011224982A Withdrawn JP2012051915A (ja) 2003-09-03 2011-10-12 ピリミジンを含有するｎｎｒｔｉとｒｔインヒビターとの組み合わせ物
JP2014222770A Expired - Lifetime JP5820045B2 (ja) 2003-09-03 2014-10-31 ピリミジンを含有するｎｎｒｔｉとｒｔインヒビターとの組み合わせ物

Country Status (24)

Country Link
US (9) US20080200435A1 (https=)
EP (1) EP1663240B2 (https=)
JP (3) JP5507791B2 (https=)
KR (1) KR20060090658A (https=)
CN (1) CN101060844B (https=)
AP (1) AP2109A (https=)
AU (5) AU2004268390B2 (https=)
BE (1) BE2015C053I2 (https=)
CA (1) CA2537095C (https=)
CY (5) CY2015039I1 (https=)
FI (1) FI1663240T4 (https=)
FR (5) FR15C0071I2 (https=)
HR (1) HRP20150798T4 (https=)
HU (5) HUS1500053I1 (https=)
IL (2) IL173438A (https=)
LT (2) LTPA2016045I1 (https=)
LU (3) LU92853I2 (https=)
MX (1) MXPA06002437A (https=)
MY (1) MY169670A (https=)
NL (2) NL300781I2 (https=)
NO (6) NO334877B1 (https=)
NZ (1) NZ545306A (https=)
PL (1) PL1663240T5 (https=)
WO (1) WO2005021001A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
KR101140785B1 (ko) 2002-08-09 2012-05-03 얀센 파마슈티카 엔.브이. 4-〔〔4-〔〔4-（2-시아노에테닐）-2,6-디메틸페닐〕아미노〕-2-피리미디닐〕아미노〕벤조니트릴의 제조방법
MXPA05007016A (es) 2003-01-14 2005-09-12 Gilead Sciences Inc Composiciones y metodos para terapia antiviral de combinacion.
ATE550074T1 (de) * 2004-09-02 2012-04-15 Janssen Pharmaceutica Nv Fumarat aus 4-((4-((4-(2-cyanoethenyl)-2,6- dimethylphenyl amino -2-pyrimidinyl amino benzonitril
WO2006024667A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
CA2577288C (en) * 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
UA92469C2 (en) * 2004-09-02 2010-11-10 Янссен Фармацевтика Н.В. Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile
ATE508748T1 (de) * 2004-09-02 2011-05-15 Janssen Pharmaceutica Nv Salz von 4-ää4-ää4-(2-cyanoethenyl)-2,6- dimethylphenylüaminoü-2- pyrimidinylüaminoübenzonitril.
TW201414495A (zh) * 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
ATE474560T1 (de) * 2005-12-14 2010-08-15 Cipla Ltd Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit
BRPI0707179A2 (pt) * 2006-01-20 2011-04-26 Tibotec Pharm Ltd tratamento de longo termo de infecção por hiv
US9044509B2 (en) 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
CL2008000746A1 (es) * 2007-03-14 2008-09-22 Tibotec Pharm Ltd Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
SG10201408158SA (en) 2008-01-03 2015-03-30 Univ Aix Marseille Composition and methods used during anti-hiv treatment
WO2010072844A1 (en) * 2008-12-24 2010-07-01 Tibotec Pharmaceuticals Implantable devices for treating hiv
UA112155C2 (uk) 2009-12-21 2016-08-10 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Розкладаний видалюваний імплантат для безперервного вивільнення активної сполуки
PE20121524A1 (es) 2010-01-27 2012-12-03 Viiv Healthcare Co Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos
SG10201509521WA (en) 2010-11-19 2015-12-30 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
WO2013038425A1 (en) * 2011-09-16 2013-03-21 Hetero Research Foundation Rilpivirine hydrochloride
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
SG11201802983TA (en) 2015-11-09 2018-05-30 Gilead Sciences Inc Therapeutic compositions for treatment of human immunodeficiency virus
WO2018077815A1 (en) 2016-10-24 2018-05-03 Janssen Sciences Ireland Uc Dispersible compositions
WO2018119371A1 (en) * 2016-12-23 2018-06-28 Temple University - Of The Commonwealth System Of Higher Education Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)
RU2019136678A (ru) * 2017-04-18 2021-05-18 Сипла Лимитед Комбинированная терапия для применения в лечении ретровирусных инфекций
WO2019021319A1 (en) * 2017-07-27 2019-01-31 Cipla Limited PHARMACEUTICAL COMPOSITIONS
CN115397422A (zh) 2019-11-29 2022-11-25 西皮欧生命科学有限公司 包含利匹韦林的组合物和其用于治疗肿瘤或癌症的用途

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182111A (en) * 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5368864A (en) * 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
EP0489181B1 (en) 1990-07-19 1996-10-02 Otsuka Pharmaceutical Co., Ltd. Solid preparation
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP0610441A4 (en) * 1991-10-29 1996-01-10 Clover Cons Ltd CROSSLINKABLE POLYSACCHARIDES, POLYCATIONS AND LIPIDS CAN BE USED TO ENCODE AND DISPENSE MEDICINAL PRODUCTS.
ATE184787T1 (de) 1992-05-13 1999-10-15 Wellcome Found Therapeutische kombinationen
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
TW401303B (en) * 1994-07-01 2000-08-11 Janssen Pharmaceutica Nv Anti-HIV triple combination
IT1281502B1 (it) * 1995-06-13 1998-02-18 Sardinian Antiviral Research C Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
ATE296091T1 (de) 1999-09-21 2005-06-15 Skyepharma Canada Inc Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe
US6743446B2 (en) * 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TWI284048B (en) * 2000-01-27 2007-07-21 Zentaris Ag Compressed microparticles for dry injection
CN1187052C (zh) 2000-03-30 2005-02-02 布里斯托尔-迈尔斯斯奎布公司 含有司他夫定(stavudine)的持续释放微球
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
DE10050199A1 (de) 2000-10-11 2002-04-25 Ethicon Gmbh Flächiges Implantat mit im Ultraschall detektierbaren Elementen
CA2431319A1 (en) 2000-12-11 2002-06-20 Hiroto Bando Pharmaceutical composition having an improved water solubility
WO2003000235A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
EP1458361A4 (en) 2001-11-20 2007-04-25 Advanced Inhalation Res Inc COMPOSITIONS FOR DISTRIBUTING PRODUCTS WITH LASTING EFFECT
KR101140785B1 (ko) 2002-08-09 2012-05-03 얀센 파마슈티카 엔.브이. 4-〔〔4-〔〔4-（2-시아노에테닐）-2,6-디메틸페닐〕아미노〕-2-피리미디닐〕아미노〕벤조니트릴의 제조방법
WO2004022033A1 (en) * 2002-09-04 2004-03-18 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
US20050287177A1 (en) 2002-11-08 2005-12-29 Glaxo Group Unlimited And Smithkline Beecham Corp. Pharmaceutical compositions
JP2006508145A (ja) 2002-11-15 2006-03-09 テイボテク・フアーマシユーチカルズ・リミテツド 抗感染化合物としての置換インドールピリジニウム
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
BRPI0407329A (pt) 2003-02-07 2006-01-10 Janssen Pharmaceutica Nv Derivados de pirimidina para a prevenção de infecção de hiv
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
KR20120039763A (ko) 2004-06-08 2012-04-25 버텍스 파마슈티칼스 인코포레이티드 약학 조성물
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
CA2577288C (en) 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
ATE508748T1 (de) 2004-09-02 2011-05-15 Janssen Pharmaceutica Nv Salz von 4-ää4-ää4-(2-cyanoethenyl)-2,6- dimethylphenylüaminoü-2- pyrimidinylüaminoübenzonitril.
AU2005307797B2 (en) 2004-11-16 2011-06-02 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
TW201414495A (zh) 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
EP1872390A2 (en) * 2005-04-11 2008-01-02 The Board of Trustees of the Leland Stanford Junior University Multi-layer structure having a predetermined layer pattern including an agent
TW200710091A (en) 2005-04-11 2007-03-16 Tibotec Pharm Ltd (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
WO2006131806A2 (en) 2005-06-07 2006-12-14 Pfizer Products Inc. Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
CN101272769B (zh) 2005-07-28 2013-04-24 Isp投资有限公司 生物利用度提高的苯醌类化合物
BRPI0707179A2 (pt) 2006-01-20 2011-04-26 Tibotec Pharm Ltd tratamento de longo termo de infecção por hiv
EP2040671B1 (en) 2006-06-23 2018-01-24 Janssen Sciences Ireland UC Aqueous suspensions of tmc278
WO2008060360A2 (en) * 2006-09-28 2008-05-22 Surmodics, Inc. Implantable medical device with apertures for delivery of bioactive agents
CL2008000746A1 (es) 2007-03-14 2008-09-22 Tibotec Pharm Ltd Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
SI2175857T1 (sl) 2007-07-12 2014-01-31 Janssen R&D Ireland Kristalna oblika (E) 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino) 2-pirimidinil)amino)benzonitrila
WO2009046299A2 (en) 2007-10-04 2009-04-09 Boston Scientific Scimed, Inc Implantable drug depot for intrathecal drug delivery system for pain management
US20110257111A1 (en) * 2008-10-24 2011-10-20 Harbeson Scott L Hydroxyethlamino Sulfonamide Derivatives

Also Published As

Publication number Publication date
LTPA2016044I1 (lt) 2017-01-10
NO2016025I1 (https=) 2016-12-20
CY2015038I1 (el) 2016-08-31
NO2014032I1 (no) 2015-01-05
AU2014203484A1 (en) 2014-07-17
HRP20150798T4 (hr) 2023-06-09
HRP20150798T1 (hr) 2015-09-11
IL173438A (en) 2012-03-29
FR15C0072I2 (fr) 2019-05-17
NZ545306A (en) 2009-11-27
US20220008417A1 (en) 2022-01-13
IL213104A (en) 2016-02-29
NO2014032I2 (no) 2014-12-18
EP1663240B1 (en) 2015-04-22
NO2014031I2 (no) 2014-12-18
PL1663240T3 (pl) 2015-10-30
HUS1500054I1 (hu) 2016-03-29
NO2016026I1 (no) 2016-12-20
US20180228800A1 (en) 2018-08-16
FR15C0073I2 (fr) 2016-02-12
US20170100398A1 (en) 2017-04-13
EP1663240A1 (en) 2006-06-07
LU92855I2 (fr) 2015-12-21
FR16C1024I1 (fr) 2017-02-03
US20150283135A1 (en) 2015-10-08
NL300768I1 (https=) 2015-12-16
NO2014030I1 (no) 2015-01-05
CN101060844A (zh) 2007-10-24
CY2015040I2 (el) 2016-08-31
WO2005021001A1 (en) 2005-03-10
AU2016210733A1 (en) 2016-08-25
US8841310B2 (en) 2014-09-23
LU92854I2 (fr) 2015-12-21
NO20061374L (no) 2006-03-27
AU2004268390A1 (en) 2005-03-10
FR15C0072I1 (https=) 2015-04-12
AU2016210733B2 (en) 2018-11-08
AU2019200813A1 (en) 2019-02-28
CY2015038I2 (el) 2016-08-31
BE2015C053I2 (https=) 2023-12-14
CA2537095C (en) 2012-05-29
CY2016049I2 (el) 2017-07-12
JP2007520443A (ja) 2007-07-26
JP2012051915A (ja) 2012-03-15
LTC1663240I2 (lt) 2022-05-25
HUS1500053I1 (hu) 2016-03-29
NL300781I1 (https=) 2016-04-19
MY169670A (en) 2019-05-08
NL300768I2 (nl) 2023-08-09
US20200171027A1 (en) 2020-06-04
MXPA06002437A (es) 2006-06-20
KR20060090658A (ko) 2006-08-14
US20080200435A1 (en) 2008-08-21
FR15C0071I1 (https=) 2015-04-12
NO2014031I1 (no) 2015-01-05
AU2004268390B2 (en) 2011-03-31
CY2015040I1 (el) 2016-08-31
CY2016049I1 (el) 2017-07-12
US20190216807A1 (en) 2019-07-18
IL173438A0 (en) 2006-06-11
AP2006003551A0 (en) 2006-04-30
CY2015039I2 (el) 2016-08-31
HUS1600058I1 (hu) 2017-02-28
JP2015044839A (ja) 2015-03-12
EP1663240B2 (en) 2023-03-01
NO2014030I2 (no) 2014-12-18
CY2015039I1 (el) 2016-08-31
CA2537095A1 (en) 2005-03-10
CN101060844B (zh) 2012-01-04
HUS1500052I1 (hu) 2016-03-29
HK1092698A1 (en) 2007-02-16
NL300781I2 (https=) 2016-04-19
CY2016048I2 (el) 2017-07-12
HUS1600059I1 (hu) 2017-02-28
NO334877B1 (no) 2014-06-23
PL1663240T5 (pl) 2024-02-26
AU2011201123A1 (en) 2011-04-07
CY2016048I1 (el) 2017-07-12
JP5820045B2 (ja) 2015-11-24
AU2011201123B2 (en) 2013-10-10
FR16C1022I1 (fr) 2017-02-03
US20100029591A1 (en) 2010-02-04
US20140349971A1 (en) 2014-11-27
AU2014203484B2 (en) 2016-09-29
LTPA2016045I1 (lt) 2017-01-10
LU92853I2 (fr) 2015-12-21
FI1663240T4 (fi) 2023-04-25
FR15C0071I2 (fr) 2016-02-12
IL213104A0 (en) 2011-07-31
AP2109A (en) 2010-02-26
FR15C0073I1 (https=) 2015-04-12

Similar Documents

Publication Publication Date Title
JP5820045B2 (ja) ピリミジンを含有するｎｎｒｔｉとｒｔインヒビターとの組み合わせ物
KR101539245B1 (ko) 피리미딘 함유 ｎｎｒｔｉ와 ｒｔ 저해제의 배합물
HK1092698B (en) Combinations of a pyrimidine containing nnrti with rt inhibitors
HK1165277A (en) Combinations of a pyrimidine containing nnrti with rt inhibitors
ZA200601820B (en) Combinations of a pyrimidine containing NNRTI with RT inhibitors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070831

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110224

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110524

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20110526

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20110610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111012

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20111028

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20111118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131016

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131115

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131216

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140320

R150 Certificate of patent or registration of utility model

Ref document number: 5507791

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term